Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Status:
Completed
Trial end date:
2020-04-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to demonstrate whether, in addition to standard of
care, finerenone is superior to placebo in delaying the progression of kidney disease, as
measured by the composite endpoint of time to first occurrence of kidney failure, a sustained
decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4
weeks, or renal death.